Navigation Links
Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
Date:4/29/2009

ug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that NeuroTrans(TM) can effectively transport diagnostic and therapeutic agents across the blood-brain barrier into the central nervous system; that the allowed claims and patents, if issued, offer strong IP protection to our NeuroTransTM program; that official patents will get issued in 2009, if at all; that NeuroTrans(TM) will help therapeutics treat CNS disorders; that strong intellectual property protections will enhance Raptor's ability to form strong collaborations with partners for further development of NeuroTrans(TM); that Raptor will collaborate with development partners; that NeuroTrans(TM) will advance to clinical trials in neurodegenerative diseases; that NeuroTrans(TM) results in previous preclinical studies will be replicated in clinical trials or in new preclinical studies; and that any of Raptor's clinical and preclinical drug candidates will result in approved therapeutics. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include: that Raptor may not be able to ra
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Provides Update of Product Programs
2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive Intelligence ... and marketplace changes. CI leaders who adjust will succeed, ... In a new Best Practices, LLC study CI leaders ... insights, including: - Use secondary research whenever ... research - Internal staff who are creative ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... - MIV Therapeutics Inc.,(OTCBB:MIVT) (FWB:MIV), a leading ... delivery systems for,cardiovascular stents and other implantable ... sponsored bench test confirmed that,merging Biosync Scientific's ... acquired, with the Company's polymer-free drug,delivery system ...
... to Company Oncology Programs to be Presented, SOUTH ... Incorporated announced,today that four posters containing non-clinical data ... the American Association,for Cancer Research (AACR) to be ... CA. These posters are related to multiple oncology,programs ...
Cached Medicine Technology:MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7
(Date:8/30/2014)... Daily Gossip reveals in its review a ... You program, who shows a unique formula to get inside ... method says that the program goes beyond mere attraction and ... You review indicates that the program was created by dating ... great techniques to make a man feel emotionally addicted. , ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 ... of Nutrition and Pharameuticals. Nutraceuticals is a source ... healthy ingredients from natural food sources. Nutraceutical ingredients ... benefits to the human body. Nutraceutical health products ... supplements, fortified foods and more. Although nature is ...
(Date:8/30/2014)... 2014 After offering hyperbaric oxygen ... the past several years, Dr. Roy Schmidt and ... announced a scholarship program for veterans who have ... meeting held this summer to discuss veterans’ needs ... have shed light on the large number of ...
(Date:8/30/2014)... August 30, 2014 Hundreds of Byetta ... continue to move forward in U.S. courts, Bernstein Liebhard ... PLC on July 31, 2014, Byetta and Bydureon (an ... product liability claims that allege the drugs caused pancreatitis, ... many of these claims are pending in a multidistrict ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... 12 Blue Cross of California,highly values the trust ... with their physicians and medical groups. It is,our responsibility ... to date,both for the benefit of our members and ... we do this is to send the member,s application ...
... ... New Event Name ... Same Commitment to ... the Health of all Babies, ... pleased to announce that 4-year-old Bradley,Coffey of Kennedy Heights and his family ... Formerly known as WalkAmerica,March for Babies is the March of Dimes premier ...
... Feb. 12 Echo Therapeutics,Inc. (OTC Bulletin Board: ... that it had completed an approximately,$2.3 million private ... VII, LLC and certain other select institutional and ... The $2,292,459 in aggregate principal amount of ...
... 12 Edwards Lifesciences,Corporation (NYSE: EW ), the ... that it has filed a patent infringement lawsuit against,CoreValve, ... Court for,the District of Delaware. The suit seeks injunctive ... family of patents for transcatheter,heart valve technology., "Edwards ...
... DARIEN, Ill., Feb. 12 Darien, IL-based Healthation,announced ... Provider Portal to deliver interactive self-service,capabilities to its ... track record of integrating with the plan,s existing ... claims directly through the,provider portal., The AboveHealth ...
... MENLO PARK, Calif., Feb. 12 XTENT, Inc.,(Nasdaq: ... results for 2007,after market close on Tuesday, February 19, ... day at 2 p.m., Pacific Time (5 p.m. Eastern ... XTENT,s President and Chief,Executive Officer, and Tim Kahlenberg, Chief ...
Cached Medicine News:Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 3Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 2Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 3Health News:Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S. 2Health News:PrimeWest Health Chooses Healthation's AboveHealth as Next Generation Provider Portal 2
Anterior Chamber Needle, 30 g. Angled. 5 mm angled tip. Overall length 20 mm. 5/box....
Anterior Chamber Needle, 23 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 20 g. Angled. 7 mm angled tip. Overall length 23 mm. 5/box....
Hydrodissection / Aspiration Cannula, 25 g. Angled with right hook. 10 mm angled shaft with 2.5 mm right hook tip. Overall length 20 mm. 5/box....
Medicine Products: